Skip to content
Homepage
Clinic directory

Clinics in Columbus, North Carolina

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Columbus, NC

Stem Cell Therapy clinics in Columbus

Columbus supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through The Ohio State University Wexner Medical Center, Nationwide Children's, and Mount Carmel, and stem cell practice in the area spans the Short North, German Village, and Dublin border. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Ohio regulates physician practice through the State Medical Board of Ohio. There is no Ohio-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Cleveland Clinic and Ohio State anchor regional academic trial activity. The 6 Columbus clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and State Medical Board of Ohio licensure checks.

No clinics found

Try adjusting your filters or search terms

Reset all filters

Regulatory context

A note on North Carolina's stem cell therapy rules.

North Carolina cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in North Carolina for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. The Research Triangle hosts substantial academic IND-based regenerative medicine research.

  • North Carolina Medical Practice Act, NC General Statutes Chapter 90, Article 1
    Establishes physician licensure and discipline through the North Carolina Medical Board.
  • North Carolina Pharmacy Practice Act, NC General Statutes Chapter 90, Article 4A
    Regulates compounding pharmacies aligned with federal 503A and 503B standards.
  • North Carolina Unfair and Deceptive Trade Practices Act, NC General Statutes Chapter 75
    Empowers the Attorney General and private plaintiffs to pursue deceptive marketing claims with treble damages available.

The FDA has issued warning letters to North Carolina clinics offering stem cell and exosome therapies. The North Carolina Medical Board has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The North Carolina Attorney General has used the Unfair and Deceptive Trade Practices Act to pursue providers making unsupported clinical claims, and Chapter 75 enables private class actions with treble damages, which raises the financial risk for noncompliant providers. Federal warning letters apply nationally.

Sources: fda.gov · ncmedboard.org · ncdoj.gov

Stem Cell Therapy in Columbus, answered.

Most stem cell therapies at private Columbus clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. They require a Biologics License or an active Investigational New Drug authorization, or they must qualify as Section 361 minimally manipulated and homologous-use products under 21 CFR Part 1271. Ohio regulates physician practice through the State Medical Board of Ohio.

In the Columbus metro, single-joint autologous bone marrow or adipose injections typically run $4,000 to $12,000 per session. Systemic IV protocols using allogeneic umbilical cord or Wharton's jelly products range $8,000 to $20,000, and full multi-session protocols can reach $15,000 to $40,000. Exosome add-ons range $3,500 to $7,500. Insurance rarely covers these treatments because the FDA classifies most protocols as investigational.

Autologous stem cells come from your own body, usually harvested from bone marrow aspirate or adipose tissue and reinjected the same day. When minimally manipulated and used for homologous function, they often fall under FDA Section 361, which does not require pre-market approval. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly, and are generally classified as Section 351 biologics that require an active Investigational New Drug authorization. Columbus clinic offerings span both categories, so ask which classification applies before treatment.

Yes. Research programs at The Ohio State University Wexner Medical Center, Nationwide Children's, and Mount Carmel periodically run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Columbus or the broader metro to see active recruiting studies. Trial participation is typically low-cost or free compared to commercial protocols and includes structured follow-up with imaging and lab monitoring.

Verify physician licensure through the State Medical Board of Ohio and confirm the clinic's NPI number through the NPPES registry. Check the FDA warning letter database for the clinic name and the HHS Office of Inspector General exclusion list. Ask whether the treatment is Section 361 or Section 351, whether the clinic operates under an Investigational New Drug authorization for allogeneic or expanded products, and whether adverse events are tracked. Ask specifically about compliance with federal 21 CFR 1271.

Treatment guide

Learn about Stem Cell Therapy

What it is, how it works, and what to expect.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology